According to the Guosheng Securities Research Report, the exchange rate disrupts short-term profits, and Gloria Ying's emerging business and order growth is impressive. Net profit due to mother for the first half of 2026 was $520 million, down 15.71% year on year. Adjusted profit and operating cash flow continued to grow under exchange rate disturbances, and operating fundamentals remained resilient. Small molecule late-stage project reserves are abundant, and the high increase in on-hand orders supports subsequent delivery. Emerging businesses are expanding at an accelerated pace, and peptides, oligonucleotides and biomacromolecules expand growth space. The company maintained rapid growth in on-hand orders and new orders. The peptide, oligonucleotide and biomacromolecule business continued to expand, and late-stage project reserves and commercial production capacity construction provided support for mid-term growth. Optimistic about the company's technology-driven advantages and emerging business development potential, and maintain a “buy” rating.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.